BEAM Beam Therapeutics Inc.

NASDAQ
$26.75

Beam Therapeutics Inc. (BEAM) is expected to report earnings on November 3, 2026, before the market open. The consensus earnings estimate is a loss of $1.16 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.1% since its last earnings release on August 4, 2026.

Beam Therapeutics Missed Consensus Estimates
Tuesday, August 4, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 3
Tuesday · 7:00 AM ET
Earnings Whisper
-
vs ($1.16)
Rev est $30.31M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $27.17

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Beam Therapeutics Inc.

Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities.

Sector

Healthcare

Industry

Biotechnology